Novel spirocyclic compounds to treat viral infections

Abstract

The present invention relates to novel compounds of the formula (I) having potential to treat viral infections especially related to dengue virus, their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

Description

[0001] ZRC-MC-241-WO NOVEL SPIROCYCLIC COMPOUNDS TO TREAT VIRAL INFECTIONS FIELD OF INVENTION The present invention relates to novel compounds of the formula (I) having potential to treat viral infections especially related to dengue virus, their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. BACKGROUND OF THE INVENTION Dengue, caused by dengue virus (DENV), is one of the most important arthropod- borne human viral infections in many tropical and subtropical areas. With approximately 390 million infections occurring each year, DENV infection puts global population at high health risk. The DENV genome encodes three structural proteins – the capsid (C), membrane (M), and envelope (E) proteins – and seven nonstructural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. There are four distinct DENV serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 with each capable of infecting person in his life time. Infection with one serotype may provide lifelong immunity against infection with a homologous DENV strain; however, only short-term immunity is maintained against heterologous infections. Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are the life- threatening outcomes of DENV infection. Severe dengue may lead to the plasma ZRC-MC-241-WO leakage, hemorrhagic tendencies, organ failure, shock, and occasionally death. Dengvaxia, is the approved tetravalent live-attenuated dengue vaccine candidate but its usage has been allowed with strict restrictions and it offers high effectiveness in preventing dengue disease caused by DENV serotypes 1–4 and is safe in people who have had a past dengue infection, i.e., those who are seropositive. US10550123 describes viral replication inhibitors and process to prepare same. WO2021094563, WO2018215315, WO2018178238, WO2017046255, WO2017046258, WO2017167951, WO2016180696 and WO2016113371 describe substituted indole and indoline derivatives for the treatment of dengue disease. WO2019244047 describes N-substituted tetrahydrothienopyridine derivatives and use thereof. WO2018178240 describes substituted indoline derivatives as dengue viral replication inhibitors. WO2017102014 describes propenamide thiophene derivatives as flavivirus inhibitors and their use. Despite the worldwide spread and the long existence of the dengue disease, there is still no specific antiviral drugs for the treatment or prevention of dengue fever virus infection. Hence, there is a great unmet medical need for therapeutics for the prevention or treatment of viral infections in animals, especially for viral infections caused by Dengue virus. Compounds with good pan anti-viral potency for DENV 1-4, minimal side-effects, a low toxicity and good ADME profile are highly needed. SUMMARY OF THE INVENTION The present invention relates to novel compounds of the general formula (I) having the potential to treat viral infections especially those related to the dengue virus, their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs, pharmaceutical compositions containing them and methods for their preparation. The compounds of the present invention are useful in the treatment of the human or animal body, by regulation of viral replication. The compounds of this invention are therefore suitable for the treatment of virus-related disorders such as Dengue. EMBODIMENTS OF THE INVENTION ZRC-MC-241-WO The main objective of the present invention is to provide novel compounds of formula (I), their tautomeric forms, their stereoisomers, novel intermediates involved in their synthesis, their suitable pharmaceutically acceptable salts and their polymorphs. In an embodiment is provided a process for the preparation of novel compounds of formula (I), their tautomeric forms, their stereoisomers, novel intermediates involved in their synthesis, their suitable pharmaceutically acceptable salts and their polymorphs. In another embodiment is provided pharmaceutical compositions comprising compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs having pharmaceutically acceptable carriers, solvents, diluents, binder, disintegrant, coating agent, filler, glidant, and / or other suitable excipients. In a further another embodiment is provided the use of the novel compounds of the present invention for the treatment of virus-related disorders such as dengue, by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable compositions. In yet another embodiment is provided a method of treating virus-related disorders such as dengue using compound of formula (I) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable compositions. DESCRIPTION OF THE INVENTION In the first embodiment, the present invention relates to compounds of the formula (I),

[0002] ZRC-MC-241-WO Wherein, X represents aryl, heteroaryl or heterocyclyl ring; R1 represents hydrogen, halogen, haloalkyl, (C1-C6)alkyl, heterocyclyl, -OR4; where (C1-C6)alkyl, heterocyclyl are independently unsubstituted or substituted with one or more suitable substituents; Y represents carbocyclic ring or heterocyclic ring, which are independently unsubstituted or substituted with one or more suitable substituents selected from (C1-C6)alkyl, -OR4, halogen; A and B represent carbocyclic or heterocyclic ring; R2 and R3 represents hydrogen, hydroxy, cyano, halo, nitro, haloalkyl, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy, -COR4, -COOR4, -OR4, -OSO2CH3, - OCOR4, -S(O)pR4, -NR4R5, -CONR4R5, -N(R4)COR5, -N(R4)COOR5, - N(R4)CONR4R5, -SO2NR4R5, -N(R4) ; which are independently unsubstituted or substituted substituents; R4 and R5 are independently selected from hydrogen, unsubstituted or substituted (C1-C6)alkyl, (C3-C6)cycloalkyl, haloalkyl; R4and R5together with the N atom to which they are attached may form a 5-8 membered heterocyclyl or heteroaryl ring; In an embodiment, when any of the (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl are substituted; the suitable substitutions on them may be selected from hydrogen, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (C1-C6)alkyl, ZRC-MC-241-WO (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy, -COR4, -COOR4, -OR4, -S(O)pR4, -NR4R5, -CONR4R5, - CON(R4)OR5, -CON(R4)SO2R5, -N(R4)COR5, -N(R4)COOR5, -N(R4)CONR4R5, - SO2NR4R5, -N(R4)SO2R5derivatives; R4and R5are same as described above; p represents integers from 0-2; l represents integers from 1-4; m represents integers from 1-5; n represents integers from 1-5. In the second embodiment, the present invention relates to compounds of the general formula (I-A); or pharmaceutically acceptable salt thereof, wherein the groups R1, R2, R3, and Y in formula (I-A) are as described in formula (I). Further preferred embodiments are those disclosed below: Preferred X is selected from aryl; Preferred Y represents carbocyclic ring or heterocyclic ring; A and B represents carbocyclic ring; Preferred R1,R2and R3may be selected from the hydrogen, cyano, halogen, (C2- C6)alkynyl, haloalkyl, heterocyclyl and -OR4, -OSO2CH3, S(O)pR4, ; ZRC-MC-241-WO Preferred R4 and R5 may be selected from hydrogen and unsubstituted or substituted (C1-C6)alkyl, (C3-C6)cycloalkyl; Preferred substitutions may be selected from hydroxy, -COOR4, -OR4, -CN, (C3- C6)cycloalkyl, heterocyclylalkyl, -CONR4R5, -CON(R4)SO2R5; p represents integers from 0-2; l represents integers from 1-4; m represents integers from 1-5; n represents integers from 1-5. In a further embodiment the groups, radicals described above may be selected from: - the “alkyl” group used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbons, selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, amyl, t-amyl, n-pentyl, n-hexyl, and the like; - the “alkenyl” group used either alone or in combination with other radicals, is selected from a radical containing from two to six carbons, more preferably groups selected from vinyl, allyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl and the like; the “alkenyl” group includes dienes and trienes of straight and branched chains; - the “alkynyl” group used either alone or in combination with other radicals, is selected from a linear or branched radical containing two to six carbon atoms, more preferably thienyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3- butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, and the like. The term “alkynyl” includes di- and tri-ynes; - the “cycloalkyl”, or “alicyclic” group used either alone or in combination with other radicals, is selected from a cyclic radical containing three to six carbons, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; - the “haloalkyl” group is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups; ZRC-MC-241-WO - "halo" or "halogen" by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom; - the “aryl” or “aromatic” group used either alone or in combination with other radicals, is selected from a suitable aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused, more preferably the groups are selected from phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl, and the like; - the “carbocyclic” group used either alone or in combination with other radicals, is selected from groups as described in “cycloalkyl” or “aryl” or “aromatic”. - the “heterocyclyl” or “heterocyclic” group used either alone or in combination with other radicals, is selected from suitable saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 4-methylpiprrazinyl, 4-hydroxypiperidinyl, 2- oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, dioxothiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thieno piperidinyl, and the like; In one embodiment, the heterocycle group, wherever applicable, may consists of appropriate number of carbon atoms and include from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, p = 0-2; - the “heteroaryl” or “heteroaromatic” group used either alone or in combination with other radicals, is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, ZRC-MC-241-WO oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, triazinyl, benzimidazolyl, benzotriazolyl, phthalazynil, naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl, benzoxazolyl, benzothiazolyl and the like; - the “aralkyl” group used either alone or in combination with other radicals, is selected from groups containing an aryl radical, as defined above, attached directly to an alkyl radical, as define above, more preferably groups selected from benzyl, phenethyl, and the like; - the “heterocyclylalkyl” group used either alone or in combination with other radicals, is selected from groups containing an heterocyclyl radical, as defined above, attached directly to an alkyl radical, as define above; - the “alkylsulfonyloxy” group used either alone or in combination, refers to an alkylsulfonyl group attached directly to an oxygen atom, wherein a suitable alkyl group as defined above is attached to a sulfonyl radical; - the “one or more suitable substituents” used either one or more suitable substituents substituted on single carbon or it may be substituted on more than one carbon; - the term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Substitution selected from hydrogen, deuterium, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (C1-C6)alkyl, (C3-C6)cycloalkyl, aminoalkyl, alkoxyalkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy; - the term “stereoisomers” used anywhere in the specification indicates that compounds of the present invention show (R) and (S) configuration; - the term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal structure. ZRC-MC-241-WO Suitable groups and substituents on the groups may be selected from those described anywhere in the specification. Preferred compounds according to the present invention include but are not limited to: 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile; 2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)acetic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopropane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; (5S)-5-(2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-one; (2S)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-2-hydroxybutanoic acid; (2S)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-2-methoxybutanoic acid; 2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-2-methylpropanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-2-methylbutanoic acid; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)cyclobutane-1-carboxylic acid; 3-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl)sulfonyl)propanoic acid; 3-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)sulfonyl)propanoic acid; ZRC-MC-241-WO 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl)propiolic acid; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanoic acid; 2-(4-chlorophenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanenitrile; 2-(4-chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(dimethylphosphoryl)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(3-hydroxypropoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5-methoxyphenyl)amino)- 1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5-methoxyphenyl)amino)-1- (6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5-methoxyphenyl)amino)-1- (6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanenitrile; 2-(4-chlorophenyl)-2-((3-((1-(hydroxymethyl)cyclopropyl)methoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; ZRC-MC-241-WO 3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; 2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(1-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; ZRC-MC-241-WO 2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclobutane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopentane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(2',3',5',6'-tetrahydrospiro [indoline-3,4'- pyran]-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; 2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; 3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; 2-(4-chloro-2-methoxyphenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-((1-(hydroxymethyl) cyclopropyl)methoxy)- 5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro [cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy) propanenitrile; 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; ZRC-MC-241-WO 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl)propanoic acid; 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-N-(methylsulfonyl)butanamide; (3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanoyl)glycine; (3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine; 2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- yl)ethan-1-one; (+) 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; (-) 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopropane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopropane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; ZRC-MC-241-WO (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; (+)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; (-)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-N- (methylsulfonyl)butanamide; (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-N- (methylsulfonyl)butanamide; (+)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)acetic acid; (-)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)acetic acid; (+)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; (-)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; (+)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-2-methylpropanoic acid; (-)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)-2-methylpropanoic acid ; (+)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; ZRC-MC-241-WO (-)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; (+)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanoic acid; (-)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanoic acid; (+)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; (-)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; (+)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl)propanoic acid; (-)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl)propanoic acid; (+)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; (-)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; (+)-(3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanoyl)glycine; (-)-(3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanoyl)glycine; (+)-(3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine; ZRC-MC-241-WO (-)-(3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine; (+)-2-(4-chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)-1- (6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)-1- (6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- yl)ethan-1-one; (+)-2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol- 1-yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- yl)ethan-1-one; (-)-2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- yl)ethan-1-one; (+)-3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro [cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; (-)-3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro [cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; (+)-3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; (-)-3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; ZRC-MC-241-WO (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(3-hydroxypropoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(3-hydroxypropoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; ZRC-MC-241-WO (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)- 5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)- 5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-((1-(hydroxymethyl)cyclopropyl)methoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-((1-(hydroxymethyl)cyclopropyl)methoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-(hydroxymethyl) cyclopropyl)methoxy)-5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; ZRC-MC-241-WO (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-(hydroxymethyl) cyclopropyl)methoxy)-5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (+)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanenitrile; (-)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)propanenitrile; (+)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy) propanenitrile; (-)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy) propanenitrile; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanenitrile; (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanenitrile; (+)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile; (-)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile; (+)-2-(1-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; (-)-2-(1-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; ZRC-MC-241-WO (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethan-1-one. The novel compounds of this invention may be prepared using the reactions and techniques as shown in scheme below and described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being affected. It is understood by those skilled in the art that the nature and order of the synthetic steps presented may be varied for the purpose of optimizing the formation of the compounds of the present invention. It will also be well appreciated that one or more of the reactants may be protected and de-protected for facile synthesis by techniques known to persons skilled in the art. It will also be appreciated that one or more of the compounds of the present invention may exist in stereoisomeric and / or diastereomeric forms. Such stereoisomers and / or diastereoisomers as well as their optical antipodes are to be construed to be within the scope of the present invention. It will also be well appreciated that one or more of these compounds may be converted to their salts and other derivatives based on the specific groups present on the compounds, which can be well comprehended by persons skilled in the art. Such salts and / or other derivatives, as the case may be should also be construed to be within the scope of the present invention. List of Abbreviations ZRC-MC-241-WO PG: Protecting Group L: Leaving Group DCC: Dicyclohexyl carbodiimide DMAP: 4-(Dimethylamino)pyridine DIPE: Diisopropyl ether BH3: Borane EDC: Ethylene dichloride EDC.HCl: Ethylene dichloride hydrochloride HMPA: Hexamethylphosphoramide TFA: Trifluoroacetic acid CDCl3: Deuterated chloroform DMF: Dimethyl formamide DCM: Dichloromethane DMSO: Dimethyl sulfoxide DMSO-d6: Hexadeuterodimethyl sulfoxide EDC: N-(3-Dimethyl aminopropyl)-N’-ethyl carbodiimide HCl: Hydrochloric acid NaOH: Sodium hydroxide TEA: Triethyl amine1H NMR: Proton Nuclear Magnetic Resonance h: Hour(s) RT: room temperature [25-300C] min: Minute(s) J: Coupling constant in units of Hz Hz: Hertz Scheme 1: Synthesis of compounds of general formula (I) ZRC-MC-241-WO The compounds of the general formula (II) can be prepared using general techniques available in the literature to prepare spiroindolines as described in J. Med. Chem.2021, 64, 7, 3658–3676 and J. Med. Chem. 2012, 55, 7667−7685. Compounds of the general formula (III) can be prepared by alpha halogenation of corresponding acetic acid derivatives using various techniques available in the literature. Compounds of the general formula (IV) can be obtained by coupling (II) with (III) using various amide bond formation techniques known in the art such as described in Tetrahedron 2005, 61, 10827 with appropriate modifications as necessary. The compounds of the general formula (I) can be obtained by reacting compounds of the formula (IV) with (V) in the presence of bases such as triethyl amine, diisopropyl ethyl amine etc, in solvents such as DMF, acetonitrile etc. Scheme 2: Synthesis of compounds of general formula (I) ZRC-MC-241-WO Alternatively, compounds of the formula (I) can be obtained by following scheme 2. The compounds of the general formula (VII) can be prepared by coupling compounds of the general formula (VI) and (V) by following a similar method as described in scheme 1 for coupling of compounds of formula (IV) and (V). Compounds of the general formula (VIII) can be obtained by deprotection using alkaline hydrolysis (PG = Me or Et) or debenzylation (PG = Bn) using hydrogenation in the presence of Pd-C. Compounds of the general formula (I) are then obtained by coupling (II) with (VIII) using various amide bond formation techniques known in the art such as described in Tetrahedron 2005, 61, 10827 with appropriate modifications as necessary. The1H NMR spectra were recorded on a Brucker Avance-400 spectrometer (400 . The chemical shifts (δ) are reported in parts per million (ppm) relative to Tetramethyl silane (TMS), in either CDCl3 or DMSO-d6 solution. Mass spectra (ESI-MS) were obtained on Shimadzu LC-MS 2010-A spectrometer. Preparation of intermediates of formula (II) Preparation of 6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indoline] (II-1) Step 1: Preparation of diethyl phenyl)malonate To a stirring solution of 1- benzene (50 g, 207 mmol) and diethyl malonate (37.90 ml, 248 mmol) in dry DMF (500 ml) was added cesium carbonate (101 g, 310 mmol) and the resulting mixture was stirred at 80°C for 3-4 h. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with ZRC-MC-241-WO water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 366.03 (M+H)+. Step 2: Preparation of 2-(2-nitro-4-(trifluoromethoxy)phenyl)acetic acid To a stirring solution of step 1 (46.35 g, 127 mmol) in methanol (400 mL) was of sodium hydroxide (20.30 g, 508 mmol) and the resulting mixture was stirred at 80°C for 4 h. After the complete conversion of the starting material methanol was evaporated from reaction mixture. The reaction mixture was diluted with cold water and acidified with dilute HCl. The solid obtained was filtered and washed with water to get the title product. MS (m / z): 266.03 (M+H)+. Step 3: Preparation of methyl 2-(2-nitro-4-(trifluoromethoxy)phenyl)acetate To a stirring solution of the 2 (33 g, 124 mmol) in DCM (330 mL) was added oxalyl chloride (16 ml, 375 mmol) at 0°Cand the resulting mixture was stirred for 2 h at room temperature. The reaction mixture was cooled to 0°C and 100 mL of methanol was added dropwise and stirred for 2 hrs at room temperature. After complete conversion of starting material, the reaction mixture was diluted with cold water and Ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 280.05 (M+H)+. Step 4: Preparation of methyl 1-(2-nitro-4- (trifluoromethoxy)phenyl)cyclopropane-1-carboxylate To a stirring solution of the 3 (31 g, 111 mmol) and 1,2- dibromoethane (11.54 ml, 133 mmol) in dry DMF (310 ml) was added cesium carbonate (109 g, 333 mmol) and the resulting mixture was stirred at 120°C for 2 ZRC-MC-241-WO h. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. MS (m / z): 306.07 (M+H)+. Step 5: Preparation of 6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-2'- one To a stirring solution of the step 4 (12.3 g, 40.3 mmol) in acetic acid (120 ml) was g, 202 mmol) and the resulting mixture was stirred at 100 °C for 2 h. After the complete conversion of starting material, the reaction mixture was filtered through celite and washed with ethyl acetate. The organic layer was distilled out and diluted with cold water. The solid obtained was filtered, washed with water, dried and column purified to get the title product. ESI-MS (m / z): 244.04 (M+H)+. Step 6: Preparation of 6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indoline] To a stirring suspension of (4.92 g, 130 mmol) in dry THF (180 ml) was added solution of the product obtained from step 5 (9 g, 37 mmol) in dry THF (90 ml) at 0 °C and the resulting mixture was stirred at 60 °C for 2 h. After the complete conversion of the starting material, the reaction mixture was diluted with 10% aq. NaOH and stirred for 1 h at RT. The reaction mixture was filtered through celite. Filtrate was extracted with ethyl acetate and evaporated under reduced pressure, dried and column purified to get the title product.1H NMR (CDCl3): 6.56-6.52 (m, 2H), 6.50-6.47 (d, 1H), 3.93 (s, 1H), 3.65 (s, 2H), 1.04-0.93 (m, 4H). ESI-MS (m / z): 230.12 (M+H)+. Using appropriate starting materials and suitable modifications of the process described for the preparation of intermediate II-1 including suitable addition and / or deletion of steps as may be necessary, well within the scope of a person skilled in ZRC-MC-241-WO the art; the following intermediates (Table 1) were prepared in an analogues manner. Table 1 Intermediates Structure ESI-MS(m / z): (M+H)+II-2 160.10 Preparatio n of intermediates of formula (III) Preparation of 2-bromo-2-(4-chlorophenyl)acetic acid (III-1) To a stirring solution of the 2- acetic acid (10 g, 58.6 mmol) in dry CCl4(100 ml) was added NBS (11.48 g, 64.5 mmol) followed by AIBN (0.48 g, 2.93 mmol) and the resulting mixture was refluxed for 12 hrs. After the complete conversion of the starting material, the reaction mixture was cooled at 0°C and the precipitated solid was filtered, filtrate was separated, washed with water and dried under reduced pressure to get the title product. ESI-MS (m / z): 248.96 (M-H). ZRC-MC-241-WO Preparation of intermediates of formula (IV) Preparation of 2-bromo-2-(4-chlorophenyl)-1-(6'-(trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one (IV-1) To a stirring solution of g, 7.20 mmol) in dry DCM (20 ml) was added g, wise at 0°C followed by DMAP (0.080 g, 0.654 mmol) and intermediate (II-1) (1.5 g, 6.54 mmol) and the resulting mixture was stirred at room temperature for 2 hrs. After the complete conversion of the starting material, the reaction mixture was diluted with cold water and the organic layer was separated. The organic layer was washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product.1H NMR (DMSO-d6): 8.02 (s, 1H), 7.62-7.59 (m, 2H).7.58-7.58 (m, 2H) 7.05-7.04 (m, 1H), 7.03-6.93 (m, 1H), 6.15 (s, 1H), 4.47-4.44 (m, 1H), 4.09-4.07 (m, 1H), 1.17-1.06 (m, 4H). ESI-MS (m / z): 461.95 (M+H)+Using appropriate starting materials and suitable modifications of the process described for the preparation of intermediate IV-1 including suitable addition and / or deletion of steps as may be necessary, well within the scope of a person skilled in the art; the following intermediates (Table 2) were prepared in an analogues manner. Table 2 Intermediates Structure ESI-MS(m / z): (M+H)+p ZRC-MC-241-WO IV-3 Directly used for next step p p Prepara yp y Step 1: Preparation of 4- butanenitrile To a stirring solution (1.0g, 5.91 mmol) and 4- bromobutanenitrile (0.61 ml, 6.21 mmol) in dry DMF (10 ml) was added cesium carbonate (2.89 g, 8.87 mmol) and the resulting mixture was stirred at 90°C for 4 hrs. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get the title product. ESI-MS (m / z): 237.06 (M+H)+Step 2: Preparation of 4-(3-amino-5-methoxyphenoxy)butanenitrile ZRC-MC-241-WO To a stirring solution of 1 (1.3 g, 5.50 mmol) in ethyl acetate (20 ml) was 27.50 mmol) and the resulting mixture was stirred at 60°C for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with aqueous ammonia and the organic layer was decanted. The organic layer was dried and distilled to get the title product. ESI-MS (m / z): 207.09 (M+H)+. Using appropriate starting materials and suitable modifications of the process described for the preparation of intermediates V-1 including suitable addition and / or deletion of steps as may be necessary, well within the scope of a person skilled in the art; the following intermediates (Table 3) were prepared in an analogues manner. Table 3 Intermediates Structure ESI-MS(m / z): (M+H)+ep ep ZRC-MC-241-WO V-6 226.11 ep ep P repara on o er- uy -(-amno--me oxyp enoxy)--me y uanoate (V-11) Step 1: tert-butyl 4-(3- To a stirring solution g, 2.96 mmol) in DMF (5 ml) was added tert-butyl 4-bromobutanoate (0.79 g, 3.55 mmol) and potassium carbonate (1.226 g, 8.87 mmol) at room temperature. The resulting mixture was stirred at 80oC for 16 hrs. After the complete conversion of the starting material, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The ZRC-MC-241-WO organic layer was separated, washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 311.91 (M+H)+. Step 2: Preparation of tert-butyl 4-(3-methoxy-5-nitrophenoxy)-2-methylbutanoate 1 (0.8 g, 2.57 mmol) in dry at -78oC under N2gas atmosphere. The resulting mixture was stirred for 1 hr at -78oC and methyl iodide (2.2 gm, 15.42 mmol) was added dropwise. The obtained reaction mixture was allowed to warm to room temperature and stirred for 16 hrs. After the complete conversion of the starting material, the reaction mixture was diluted with saturated ammonium chloride aqueous solution to pH 7-8 and extracted by ethyl acetate twice. The combined organic layer was washed with brine and evaporated under reduced pressure and purified by column chromatography to get the title product. Step 3: Preparation of tert-butyl 4-(3-amino-5-methoxyphenoxy)-2- methylbutanoate To a stirring solution 2 (0.22 g, 0.676 mmol) in ethanol (5 ml) and water (1 ml) was added iron powder (0.227 gm, 4.06 mmol) and ammonium chloride (0.217 gm, 4.06 mmol). The resulting reaction mixture was stirred at 100oC for 2 hrs. After the complete conversion of starting material, the reaction mixture was filtered through a hyflow and filtrate was concentrated under reduced pressure and used in the next step without further purification. ESI-MS (m / z): 296.10 (M+H)+. Preparation of 2-(3-amino-5-methoxyphenoxy)-2-methylpropan-1-ol (V-12) ZRC-MC-241-WO Step 1: Preparation of -2-methylpropanoate To a stirring solution of (0.5 g, 2.96 mmol) and ethyl 2-bromo-2- gm, in DMF (5 ml) was added potassium carbonate (1.02 gm, 7.39 mmol) at room temperature. The resulting mixture was stirred at 80°C for 4 hrs. After complete conversion of the starting material, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 284.13 (M+H)+. Step 2: Preparation of 2-(3-methoxy-5-nitrophenoxy)-2-methylpropan-1-ol To a stirring solution of step 1 (0.6 g, 2.118 mmol) in DCM (30 ml) was added DIBAL-H (6 ml, 5.30 mmol) at -20oC. The resulting mixture was stirred at room temperature for 3 hrs. After complete conversion of the starting material, the reaction mixture was poured into water (50 ml) at 0oC and stirred for 1 hr at room temperature. The organic layer was separated, washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product. Step 3: Preparation of 2-(3-amino-5-methoxyphenoxy)-2-methylpropan-1-ol ZRC-MC-241-WO To a stirring solution of step 2 (0.3 g, 1.244 mmol) in methanol (5 ml) was added mmol). The resulting reaction mixture was stirred under H2 gas atmosphere for 3 hrs at room temperature. After the complete conversion of starting material, the reaction mixture was filtered through a hyflow and filtrate was concentrated under reduced pressure and used in the next step without further purification. ESI-MS (m / z): 212.14 (M+H)+. Preparation of 1-(3-amino-5-methoxyphenoxy)-2-methylpropan-2-ol (V-13) Step 1: Preparation of 1- -2-methylpropan-2-ol To a stirring solution of the (0.3 g, 1.774 mmol) and 2,2- dimethyloxirane (0.19 ml, 2.128 mmol) in DMF (5 ml) was added potassium carbonate (0.61 gm, 4.43 mmol) at room temperature. The resulting mixture was stirred at 80°C for 16 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product. Step 2: Preparation of 1-(3-amino-5-methoxyphenoxy)-2-methylpropan-2-ol ZRC-MC-241-WO To a stirring solution of the product obtained from step 1 (0.3 g, 1.244 mmol) in methanol (5 ml) was added 10% Pd-C (0.013 gm, 0.1 mmol). The resulting reaction mixture was stirred under H2 gas atmosphere for 3 hrs at room temperature. After the complete conversion of starting material, the reaction mixture was filtered through hyflow and filtrate was concentrated under reduced pressure and used in the next step without further purification. ESI-MS (m / z): 212.10 (M+H)+. Preparation of methyl 3-((3-amino-5-methoxyphenyl)sulfonyl)propanoate (V- 14) Step 1: Preparation of 3-( propanoic acid To a stirring solution of 1- (200 mg, 0.862 mmol) and 3-mercaptopropionic acid (96 mg, 0.905 mmol) in dry dioxane (5 ml) was added Xantphos (42.4 mg, 0.073 mmol), Pd2(dba)3 (33.9 mg, 0.037 mmol) and DIPEA (0.467 ml, 2.67 mmol) and the resulting mixture was stirred at 90°C for 16 hrs. After completion of the reaction, the reaction mixture was diluted with cold water and ethyl acetate, the organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. Step 2: 3-((3-methoxy-5-nitrophenyl)sulfonyl)propanoic acid To a stirring solution of 1 (150 mg, 0.583 mmol) in a mixture of acetone (2 ml) and water (2 ml) was added oxone (1.07 g, 1.749 mmol) ZRC-MC-241-WO and the resulting mixture was stirred at room temperature for 4 hrs. After complete conversion of starting material, the reaction mixture was filtered and the filtrate was diluted with water and ethyl acetate, the organic layer was separated and distilled out to get the title product. ESI-MS (m / z): 288.2 (M-H). Step 3: methyl 3-((3-methoxy-5-nitrophenyl)sulfonyl)propanoate To a stirring solution of step 2 (1.6 g, 5.53 mmol) in methanol (20 ml) was ml, 8.30 mmol) and the resulting mixture was stirred at 70°C for 2 hrs. After the complete conversion of the starting material, the reaction mixture was quenched with ice water, and the product was extracted in ethyl acetate, the organic layer was separated and distilled out to get the title product Step 4: methyl 3-((3-amino-5-methoxyphenyl)sulfonyl)propanoate To a stirring solution of step 3 (1.3 g, 4.29 mmol) in methanol (20 mL) was added Pd / C (50 mg), and the resulting mixture was stirred at room temperature under hydrogen pressure for 4 hrs. After complete conversion of starting material, the reaction mixture was filtered through hyflow and filtrate was evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. ESI-MS (m / z): 274.05 (M+H)+Preparation of 3-methoxy-5-(1H-1,2,4-triazol-1-yl)aniline (V-15) ZRC-MC-241-WO Step 1: Preparation of 1-bromo-3,5-dinitrobenzene To a solution of 1,3- mmol) in sulfuric acid (50 mL) was added NBS (11.86 g, 66.6 at 85°C. The reaction mixture was stirred for 1 hour at 85°C. Cooled the reaction mixture and poured into ice water and precipitate compound was filtered, dried to get the desired product. Step 2: Preparation of 1-bromo-3-methoxy-5-nitrobenzene To a stirring solution of the step 1 (3.00 g, 12.15 mmol) in methanol (50 ml) was added (3.94 g, 18.22 mmol) at 15°C and the reaction mixture was stirred at 70°C for 2 hrs. Reaction mixture was cooled and poured it into ice water and extracted with ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the desired product. Step 3: Preparation of 1-(3-methoxy-5-nitrophenyl)-1H-1,2,4-triazole To a stirring solution of the step 2 (1.00 g, 4.31 mmol) in N- Methyl-2-pyrrolidinone (6.00 ml) was added potassium carbonate (1.787 g, 12.93 mmol), 1,2,4-triazole (0.893 g, 12.93 mmol) and CuI (0.410 g, 2.155 mmol). The reaction mixture was stirred at 100°C for 16 hrs. After completion of the starting material, it was filtered through celite and washed with THF. Filtrate was concentrated and the crude product was purified by column chromatography to get the desired product. ESI-MS (m / z): 221.08 (M+H)+Step 4: Preparation of 3-methoxy-5-(1H-1,2,4-triazol-1-yl)aniline ZRC-MC-241-WO To a stirring solution of the step 3 (0.420 g, 1.907 mmol) in THF (3.0 ml) and methanol Pd-C (0.122 g, 1.144 mmol). The reaction mixture was stirred under hydrogen pressure at 25°C for 3 hrs. After completion of reaction, it was filtered through hyflow and filtrate was evaporated to get the desired product. ESI-MS (m / z): 191.09 (M+H)+Preparation of (3-amino-5-methoxyphenyl)dimethylphosphine oxide (V-16) Step 1: preparation of (3- dimethylphosphine oxide To a stirring solution of 1- nitrobenzene (0.500 g, 2.155 mmol) in DMF (5.00 ml) was added xantphos (0.125 g, 0.215 mmol), Pd(OAc)2 (0.024 g, 0.108 mmol), potassium phosphate hydrate (0.546 g, 2.370 mmol) and dimethylphosphine oxide (0.202 g, 2.59 mmol) at 25°C . The above reaction mixture was stirred at 130°C for 1h. After completion of the reaction, it was filtered through celite and washed with ethyl acetate, concentrated under reduced pressure to get crude product was purified by column chromatography to get the desired product. ESI-MS (m / z): 230.06 (M+H)+Step 2: Preparation of (3-amino-5-methoxyphenyl)dimethylphosphine oxide ZRC-MC-241-WO To a stirring solution of the step 1 (0.450 g, 1.964 mmol) in ethanol (10 ml) was added Pd-C mmol) at 25°C. Reaction mixture was stirred under hydrogen pressure at 25°C for 3 hrs. After completion of the reaction, it was filtered through hyflow and filtrate was evaporated to get the desired product. ESI-MS (m / z): 200.00 (M+H)+Preparation of 3-(3-amino-5-methoxyphenyl)prop-2-yn-1-ol (V-17) Step 1: Preparation of 3,5-dinitroaniline To a stirring solution of 3,5- (37.5 g, 177 mmol), oleum (70 ml, 46.9 mmol) and sulfuric acid (15 ml, 281 mmol) in dry chloroform (125 ml) was added sodium azide (3.66 g, 56.3 mmol) portion wise at 35°C and the resulting mixture was stirred at 60°C for 2 hrs. After completion of the reaction, the reaction mixture was diluted with cold water. The solid obtained was filtered, washed with water and dried to get the title product. ESI-MS (m / z): 184.05 (M+H)+Step 2: Preparation of 1-iodo-3,5-dinitrobenzene To a stirring solution of the step 1 (10 g, 54.6 mmol) in HCl (41.5 ml, 1365 mmol) was added sodium nitrite (5.65 g, 82 mmol) in 20 ml water ZRC-MC-241-WO at 0°-5°C. The resulting mixture was stirred at 0°C for 30 min. Potassium iodide (22.66 g, 137 mmol, in 40 ml water) was added dropwise at 0°C. The resulting mixture was stirred at 60°C for 2 hrs. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product.1H NMR (DMSO-d6): 8.91-8.89 (t, J= 2.0Hz ,2H), 8.79-8.76 (m, 1H). Step 3: Preparation of 1-iodo-3-methoxy-5-nitrobenzene To a stirring solution of the from step 2 (5 g, 17.01 mmol) in methanol (50 ml) was added (1.378 g, 25.5 mmol) portion- wise at 0°C. The resulting mixture was stirred at 60°C for 24 hrs. After the complete conversion of the starting material, the reaction mixture was cooled, solid obtained was filtered, washed with methanol and dried to get the title product.1H NMR (DMSO-d6): 8.08-8.07 (t, J=1.6 Hz, 1H), 7.79-7.78 (m, 1H), 7.72-7.71 (t, J= 2.0Hz, ol A stirring solution of the product obtained from step 3 (1 g, 3.58 mmol) in TEA (5 ml) was added copper iodide (0.068 g, 0.358 mmol) and triphenylphosphine palladium chloride (0.126 g, 0.179 mmol) followed by prop-2-yn-1-ol (0.301 g, 5.38 mmol). The resulting mixture was stirred at 60°C for 1 hr. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate, the organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ZRC-MC-241-WO 1H NMR (DMSO-d6): 7.77-7.76 (m, 1H), 7.72-7.71 (t, J= 2.4 Hz, 1H), 7.44-7.43 (m, 1H), 5.45-5.42 (t, J= 2.0 Hz, 1H), 3.89 (s, 3H). Step 5: Preparation of 3-(3-amino-5-methoxyphenyl)prop-2-yn-1-ol To a stirring solution of step 4 (0.5 g, 2.413 mmol) in ethyl acetate (5 ml) was (2.72 g, 12.07 mmol) and the resulting mixture was stirred at 80°C for 2 hrs. After the complete conversion of starting material, the reaction mixture was diluted with aqueous ammonia and the organic layer was decanted. and distilled out to get the title product ESI-MS (m / z): 178.10 (M+H)+Preparation of 4-(3-amino-5-methoxyphenyl)but-3-yn-1-ol (V-18) Step 1: Preparation of 4- 3-yn-1-ol (1 g, 3.58 mmol), copper iodide (0.068 g, 0.358 mmol), triphenylphosphine palladium chloride (0.126 g, 0.179 mmol) in THF (10 ml) was added potassium carbonate (0.991 g, 7.17 mmol) followed by but-3-yn-1-ol (0.502 g, 7.17 mmol). The resulting mixture was stirred at 60°C for 1 hr. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 222.08 (M+H)+ ZRC-MC-241-WO Step 2: Preparation of 4-(3-amino-5-methoxyphenyl)but-3-yn-1-ol To a stirring solution of 1 (0.5 g, 2.26 mmol) in ethyl acetate (5 ml) was added 11.30mmol) and the resulting mixture was stirred at 80°C for 2 hrs. After complete conversion of starting material, the reaction mixture was diluted with aqueous ammonia and the organic layer was decanted and distilled out to get the title product ESI-MS (m / z): 192.3 (M+H)+Preparation of ethyl 3-(3-amino-5-methoxyphenyl)propiolate (V-19) propiolate A stirring solution of the 1-iodo-3-methoxy-5-nitrobenzene (1 g, 3.58 mmol), copper iodide (0.068 g, 0.358 mmol), triphenylphosphine palladium chloride (0.126 g, 0.179 mmol) in THF (10ml) was added potassium carbonate (0.991 g, 7.17 mmol) followed by ethyl propiolate (0.527 g, 5.38 mmol). The resulting mixture was stirred at 60°C for 1 hr. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 250.09 (M+H)+Step 2: Preparation of ethyl 3-(3-amino-5-methoxyphenyl)propiolate ZRC-MC-241-WO To a stirring solution of step 1 (0.6 g, 2.407 mmol) in ethyl acetate (6 ml) was g, 12.04 mmol) and the resulting mixture was stirred at 80°C for 2 hrs. After the complete conversion of the starting material, the reaction mixture was diluted with aqueous ammonia and the organic layer was decanted. The organic layer was dried and distilled out to get the title product ESI-MS (m / z): 220.16 (M+H)+Preparation of 3-(3-amino-5-methoxyphenoxy)propanenitrile (V-20) Step 1: Preparation of 3-(3- propan-1-ol To a stirring solution of g, 7.09 mmol) in DMF (10 ml) was added potassium carbonate (2.451 g, 17.74 mmol) and 3-bromopropan-1- ol (0.706 ml, 7.80 mmol). The reaction mixture was stirred at 80°C for 5 hrs. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was evaporated under reduced pressure to get crude product which was purified by column chromatography to get desired product. ESI-MS (m / z): 228.06 (M+H)+. Step 2: Preparation of 3-(3-methoxy-5-nitrophenoxy)propanenitrile To a stirring solution of 1 (0.550 g, 2.421 mmol) in acetonitrile:water (5.50, ml 0.6 ml) was added ammonium acetate (0.746 g, 9.68 mmol), iodobenzene diacetate (1.715 g, 5.33 mmol) and TEMPO (0.019 g, 0.121 ZRC-MC-241-WO mmol). The reaction mixture was stirred at 25°C for 2 hrs. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and water. Organic layer was evaporated to get crude product which was purified by column chromatography to get the desired product. Step 3: Preparation of 3-(3-amino-5-methoxyphenoxy)propanenitrile To a stirring solution of 2 (0.330 g, 1.485 mmol) in tetrahydrofuran (3.0 ml) added Pd-C (0.079 g, 0.743 mmol). The reaction was stirred under hydrogen balloon at 25°C for 3 hrs. After completion of the reaction, it was filtered through hyflow and filtrate was evaporated to get the desired product. ESI-MS (m / z): 193.06 (M+H)+Preparation of ethyl 3-(3-amino-5-methoxyphenoxy) propanoate (V-21) Step 1: Preparation of acrylate To a stirring solution of g, 2.956 mmol) and ethyl propiolate (0.29 g, 2.956 mmol) in dry DCM (10 ml) was added DABCO (16.58 mg, 0.148 mmol) at room temperature and stirred for 16 hrs. After the complete conversion of the starting material, the reaction mixture was diluted with water and layers were separated. The organic layer was washed with brine and evaporated under reduced pressure to give oily material which was purified by column chromatography to get the title product. ESI-MS (m / z): 268.05 (M+H)+. Step 2: Preparation of ethyl 3-(3-amino-5-methoxyphenoxy) propanoate ZRC-MC-241-WO To a stirring solution of 1 (0.6 g, 2.245 mmol) in methanol (10 ml) was 2.83 mmol). The resulting reaction mixture was stirred under H2 gas atmosphere for 3 hrs at room temperature. After the complete conversion of starting material, the reaction mixture was filtered through a hyflow and filtrate was concentrated under reduced pressure to give oily material which was purified by column chromatography to get the title product. ESI-MS (m / z): 240.10 (M+H)+. Preparation of (S)-5-(2-(3-amino-5-methoxyphenoxy)ethyl)-2,2-dimethyl-1,3- dioxolan-4-one (V-22) Step 1: preparation of (S) dioxolan-4-yl)acetic acid To a stirring solution of L- mmol) and p-toluenesulfonic acid monohydrate (0.213 mg, 1.11 mmol) was added 2,2-dimethoxypropane (110 mL, 895 mol) at room temperature. The reaction mixture was stirred at room temperature for 16 hrs. After complete conversion of starting material, water (40 mL) and dichloromethane (150 ml) were added. Evaporated the DCM layer and diluted with ether (1:1) (50 mL) and hexane (50 ml) to get the crystals.. ESI-MS (m / z): 173.06 (M-H) Step 2: Preparation of (S)-5-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-one ZRC-MC-241-WO To a stirring solution of borane dimethyl sulfide complex (8.61 ml, 17.23 mmol) in THF (7.00 ml) was added trimethyl borate (1.925 ml, 17.23 mmol) and the product obtained from step-1 (2.00 g, 11.48 mmol) dissolved in THF (16 ml) dropwise in 15 mins at 0 °C. The reaction mixture was stirred for 16 hrs at 25°C. After complete conversion of the starting material methanol (100 ml) was added at 0°C and stirred for 1 hr. Ethyl acetate (100 ml) was added and evaporated the reaction mixture to get the title product Step 3: Preparation of (S)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)ethyl 4- methylbenzenesulfonate 2 (11 g, 68.7 mmol) in pyridine (13.09 g, 68.7 mmol) portion wise. The reaction mixture was stirred at 25°C for 2 hrs. After completion of the reaction, reaction mixture was diluted with DCM (100 ml) and acidified with 50 % HCl solution. The organic layer was separated and evaporated under reduced pressure to get the crude product. The crude product was purified by column chromatography to get the desired product. ESI-MS (m / z): 315.10 (M+H)+Step 4: Preparation of (S)-5-(2-(3-methoxy-5-nitrophenoxy)ethyl)-2,2-dimethyl- 1,3-dioxolan-4-one g, 2.96 mmol) and product obtained from step-3 (1.208 g, 3.84 mmol) in acetonitrile (10 ml) was added potassium carbonate (0.940 g, 6.80 mmol) at 25°C. The reaction mixture was stirred at 80°C for 16 hrs. After completion of the reaction, it was diluted with ethyl acetate and water. Organic layer separated and evaporated and purified by column chromatography to get the desired product. ZRC-MC-241-WO Step 5: preparation of (S)-5-(2-(3-amino-5-methoxyphenoxy)ethyl)-2,2-dimethyl- 1,3-dioxolan-4-one To a stirring solution of 4 (80 mg, 0.267 mmol) in THF (1.0 ml) and MeOH mg, 0.267 mmol) at 25°C. The reaction mixture was stirred for 3 hrs under hydrogen pressure at room temperature. After the complete conversion of starting material, the reaction mixture was filtered through hyflow and the filtrate was evaporated to get the desired product. ESI-MS (m / z): 282.10 (M+H)+. Preparation of methyl (S)-4-(3-amino-5-methoxyphenoxy)-2- methoxybutanoate (V-23) Step 1: Preparation 5- nitrophenoxy)butanoate 4 of intermediate V-22 (0.250 g, 0.803 mmol) in methanol (5.00 ml) was added sodium methoxide (0.191 g, 0.883 mmol) at 5°C. The reaction mixture was stirred for 2 hrs at 25°C. After completion of the reaction diluted with ethyl acetate and dilute HCl. The organic layer was separated and evaporated, purified by column chromatography to get the desired product. Step 2: Preparation of methyl (S)-2-methoxy-4-(3-methoxy-5- nitrophenoxy)butanoate ZRC-MC-241-WO To a stirring solution 1 (85 mg, 0.298 mmol) in DMF (2.00 ml) was mg, 0.745 mmol), dimethyl sulfate (0.043 ml, 0.447 mmol) and the reaction mixture was stirred for 5 hrs at 80°C. After completion of the reaction, a product extracted with ethyl acetate and washed with water. The organic layer was evaporated and purified by column chromatography to get the desired product. Step 3: Preparation of methyl (S)-4-(3-amino-5-methoxyphenoxy)-2- methoxybutanoate 2 (80 mg, 0.267 mmol) in THF (1.0 ml) and MeOH (1.0 ml) was added Pd-C (28.4 mg) at 25°C. The reaction mixture was stirred for 3 hrs under hydrogen pressure at room temperature. After the complete conversion of starting material, the reaction mixture was filtered through hyflow and filtrate was evaporated to get the desired product. ESI-MS (m / z): 270.00 (M+H)+. Preparation of 3-amino-5-methoxyphenyl methanesulfonate (V-24) Step 1: Preparation of 3- ZRC-MC-241-WO To a stirring solution of 3-methoxy-5-nitrophenol (0.550 g, 3.25 mmol) in DCM (10 ml) was added triethylamine (0.680 ml, 4.88 mmol) and methane sulfonyl chloride (0.279 ml, 3.58 mmol) and the reaction stirred at 25°C for 2 hrs. After completion of the reaction, it was diluted with water and the organic layer separated and evaporated to get the desired product. ESI-MS (m / z): 247.99 (M+H)+Step 2: Preparation of 3-amino-5-methoxyphenyl methanesulfonate To a stirring solution of 1 (0.700 g, 2.83 mmol) in THF (3.0 ml) and methanol (3.0 ml) g, 0.849 mmol). The reaction mixture was stirred for 3 hrs under hydrogen pressure at room temperature. After the complete conversion of starting material, the reaction mixture was filtered through hyflow and the filtrate was evaporated to get the desired product. ESI-MS (m / z): 218.03 (M+H)+Preparation of intermediates of formula (VI) Preparation of methyl 2-bromo-2-(4-chloro-2-methoxyphenyl)acetate (VI-1) Step 1: Preparation of methyl 2-(4-chloro-2-methoxyphenyl)acetate To a stirring solution of 2- acetic acid (2.5 g, 10.02 mmol) in dry DCM (15 ml) was added oxalyl chloride (1.03 mL, 12.02 mmol) and the resulting mixture was stirred at RT for 1 hr. The reaction mixture was cooled to 0°C and methanol (0.64 mL, 20.04 mmol) was added to the reaction mixture and ZRC-MC-241-WO stirred for 4 hrs at RT. After the complete conversion of the starting material, the reaction mixture was diluted with cold water and the organic layer was separated. The organic layer was distilled out to get the title product. ESI-MS (m / z): 215.13 (M+H)+Step 2: Preparation of methyl 2-bromo-2-(4-chloro-2-methoxyphenyl)acetate Prepared using a similar intermediate III-1 using methyl 2-(4-chloro-2-methoxyphenyl) as material. ESI-MS (m / z): 292.95 (M+H)+Preparation of ethyl 2-bromo-2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4- chlorophenyl)acetate (VI-2) Step 1: Preparation of ethyl acetate To a stirring solution of the 2-methoxyphenyl)acetate (3.6 g, 15.74 mmol) in dry DCM (50 ml) was added BBr3(31.5 mL, 31.5 mmol) at -30°C and the resulting mixture was stirred at room temperature for 2 hrs. After completion of reaction, the reaction mixture was diluted with cold water. The organic layer was separated, washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 215.05 (M+H)+ ZRC-MC-241-WO Step 2: Preparation of ethyl 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4- chlorophenyl)acetate To a stirring solution of step 1 (2.6 g, 12.11 mmol) in dry DMF (30 ml) was butyl)dimethylsilane (4.5 gm, 18.17 mmol) followed by cesium carbonate (7.89 mg, 24.23 mmol) and the resulting mixture was stirred at RT for 12 hrs. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 373.10 (M+H)+Step 3: ethyl 2-bromo-2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4- chlorophenyl)acetate To a stirring solution of the step 2 (2.8 g, 7.5 mmol) in dry THF (20 ml) was added LiHMDS in THF (15 ml, 15.01 mmol) dropwise at -78°C. To this was added TMS-Cl (1.31 g, 12.01 mmol) in dry THF (4 ml) at -78°C and the reaction mixture was stirred for 15 min. at the same temperature. NBS (2.01 g, 11.24 mmol) in dry THF (10 ml) was added dropwise at -78°C to the reaction mixture and stirred for 1 h at -78°C. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 451.05 (M+H)+ ZRC-MC-241-WO Preparation of compounds EXAMPLE 1 Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid Step-1: -2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoate To a stirring 1 (1.00 g, 2.171 mmol) and intermediate-V-4 (0.616 g, 1.954 mmol) in DMF (10 ml) was added TEA (0.329 g, 3.26 mmol) at room temperature. The resulting mixture was stirred at 100 °C for 16 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with brine solution, evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 695.3 (M+H)+. ZRC-MC-241-WO Step 2: Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid To a stirring g, 0.863 mmol) in methanol (5 ml) was g, room temperature. The resulting mixture was stirred at room temperature under hydrogen pressure by balloon (30 psi) for 12 hrs. After complete conversion of starting material, the reaction mixture was filtered through pad of celite and filtrate was evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product.1H NMR (CDCl3): 8.20 (s, 1H), 7.54-7.52 (d, 2H).7.48-7.28 (m, 2H) 6.91-6.89 (d, 1H), 6.64-6.62 (d, 1H), 5.90-5.84 (m, 3H), 5.13 (s, 1H), 4.30-4.28 (d, 1H), 3.98-3.94 (m, 3H), 3.73 (s, 3H), 2.60-2.56 (t, 2H), 2.13-2.06 (m, 2H), 1.18-1.01 (m, 4H). ESI-MS (m / z): 605.5 (M+H)+. EXAMPLE 2 Preparation of 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile Step 1: -2-((3-(3- cyanopropoxy)-5-methoxyphenyl)amino)acetate ZRC-MC-241-WO To a stirring solution of VI-1 (1.4 g, 4.85 mmol) in DMF (15 mL) was g, 4.36 mmol) followed by triethyl amine (2.02 mL, 14.55 mmol) and the resulting mixture was heated at 80°C for 3 hr. After the complete conversion of starting material, the reaction mixture was diluted with cold water and extracted with ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. ESI- MS (m / z): 419.12. (M+H)+Step 2: Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-cyanopropoxy)-5- methoxyphenyl)amino)acetic acid To a stirring solution of 1 (1.7 g, 4.06 mmol) in 50% methanol: THF (10 mL) was added 4 ml aqueous solution of sodium hydroxide (0.3 g, 12.18 mmol) and the resulting mixture was stirred at 40°C for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water, acidify with aqueous HCl and extracted with DCM. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. ESI- MS (m / z): 405.10 (M+H)+Step 3: Preparation of 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile ZRC-MC-241-WO To a stirring mg, 1.53 mmol) in DMF (5 ml) was followed by HATU (874 mg, 2.29 mmol) and DIPEA (0.8 mL, 4.59 mmol) at 0-10°C. Reaction mixture was stirred at same temperature for 1 hr. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product.1H NMR (CDCl3): 8.16 (s, 1H), 7.37 (d, J =8.0 Hz, 1H), 6.97 (dd, J =1.6 & 8.0 Hz, 1H), 6.93 (d, J =1.6 Hz, 1H), 6.88 (dd, J =0.8 & 8.0 Hz, 1H), 6.61 (d, J =8.0 Hz, 1H), 5.94-5.90 (m, 3H), 5.61 (s, 1H), 4.23 (d, J =10 Hz, 1H), 4.03-4.00 (m, 2H), 3.99-3.93 (m, 4H), 3.73 (s, 3H), 2.57 (t, J =7.2 Hz, 2H), 2.14-2.08 (m, 2H), 1.15-1.06 (m, 4H). ESI- MS (m / z): 616.15 (M+H)+. EXAMPLE 3 Preparation of 2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid ZRC-MC-241-WO Step-1: Preparation of ethyl 2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetate To a stirring IV-1 (0.5 g, 1.08 mmol) and g, ml) was added TEA (0.18 mL, 1.3 mmol) at room temperature. The resulting mixture was stirred at 100 °C for 16 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with brine solution, evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 605.2 (M+H)+. Step 2: 2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid 0.066 mmol) in THF (0.5 ml) was added LiOH (4.75 mg, 0.198 mmol) in water (0.25 ml), and the reaction was stirred at 25°C for 2 hrs. After completion of the reaction, it was diluted with water and acidified by dil. HCl to pH=3. The product was extracted with ethyl acetate and purified by column chromatography to get the desired product.1H NMR (CDCl3): 8.18 (s, 1H), 7.42 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.8 ZRC-MC-241-WO Hz, 2H), 6.89 (dd, J =1.2 & 8.4 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 5.89-5.83 (m, 3H), 5.09 (s, 1H), 4.58 (s, 2H), 4.26 (d, J =9.6 Hz, 1H), 3.94 (d, J =9.6 Hz, 1H), 3.72 (s, 3H), 1.17-1.01 (m, 4H). ESI-MS (m / z): 577.15 (M+H)+Using appropriate starting materials and suitable modifications of the process described for the preparation of Examples 1, 2 and 3 including suitable addition and / or deletion of steps as may be necessary, well within the scope of a person skilled in the art; the following compounds were prepared in an analogues manner. EXAMPLE 4 Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopropane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid Prepared using1 H NMR (DMSO-d6): 11.71 (s, 1H), 8.03 (s, 1H), 7.54.-5.51 (d, J= 8.4 Hz, 2H), 7.45-7.43 (d, J=8.4 Hz, 2H ), 6.99-6.98 (d, J=8.4 Hz, 1H), 6.63-6.61 (d, J=8 Hz, 1H), 5.76 (s, 2H), 5.75 (s, 1H), 5.42 (s, 1H), 4.53-4.50 (d, J=8 Hz, 1H), 4.12-4.09 (d, J=8 Hz, 2H), 3.61 (s, 3H), 3.35 (s, 3H), 2.51-2.49 (m, 2H), 1.91-1.89 (m, 2H), 1.17-1.13 (m, 4H). ESI- MS (m / z): 521.18 (M+H)+. EXAMPLE 5 Preparation of (5S)-5-(2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-one ZRC-MC-241-WO Prepared using NMR (DMSO-d6): 8.02 (s, 1H ), , 2H ), 6.99-6.91(m, 2H ), 6.57-6.50(m,1H ), 5.93-5.90(m,2H), 5.75-5.74(d, J=8Hz, 1H), 5.48-5.46(d, J= 8 Hz,1H ), 4.71-4.70(d, J=4.0 Hz,1H), 4.53 (s,1H ), 4.10(s,1H), 3.96-3.93(m, 2H ), 3.616-3.614 (d, J=0.8Hz, 3H), 2.20-2.00 (m, 2H), 1.51-1.45 (m, 6H), 1.09- 1.08(m, 4H). ESI-MS (m / z): 661.30 (M+H)+. EXAMPLE 6 Preparation of (2S)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-hydroxybutanoic acid To a stirring mg, 0.076 mmol) in THF (0.5 ml) was added NaOH (3.03 mg, 0.076 mmol) in water (0.25 ml), and the reaction was stirred at 25°C for 2 hours. After completion of the reaction, it was diluted with water and acidified by diluting HCl to pH=3. The product was extracted with ethyl acetate and purified by column chromatography to get the ZRC-MC-241-WO desired product.1H NMR (DMSO-d6): 8.02 (s, 1H ), 7.54-7.52 (d, J=8 Hz, 2H), 7.45-7.43 (d, J=8 Hz, 2H) 7.10-6.98 (m, 1H), 6.93-6.91(d, J=8 Hz, 1H ), 6.51 -6.49 (d, J= 8 Hz,1H ), 5.94-5.90 (d, J=8 Hz, 2H ), 5.76-5.75 (m, 1H), 5.50-5.48 (d, J= 12 Hz,1H), 4.54-4.51 (d, J=12 Hz,1H ), 4.13-4.10 (d, J=12 Hz, 1H), 4.07-4.04 ( m , 1H), 3.99-3.86 (m ,2H), 3.61 (s, 3H), 2.08-2.03 (m, 1H), 1.85-1.76 (m, 1H), 1.24- 1.23 (s, 1H), 1.17-1.06 (m, 4H). ESI-MS (m / z): 621.2 (M+H)+. : (s, methoxyphenoxy)-2-methylpropanoic acid ZRC-MC-241-WO Prepared using NMR (DMSO-d6): 8.00 (s, 1H), 7.53-7.51 , , 7.00-6.97 (t, J= 8.0, 1H) , 6.92-6.90 (d, J= 8.4, 1H), 6.48-6.45 (d, J= 8.8, 1H), 5.90 (s, 1H), 5.81 (s, 1H), 5.66-5.65 (t, J= 2.0, 1H), 5.40-5.38 (d, J= 8.4, 1H), 4.51-4.52 (d, J= 10.8, 1H), ), 4.09-4.06 (d, J= 10.4, 1H), 3.57 (s, 3H), 1.39 (s, 6H), 1.19-1.07 (m, 4H). ESI-MS (m / z): 605.13 (M+H)+EXAMPLE 9 Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylbutanoic acid Prepared using NMR (CDCl3): 8.19 (s, 1H), 7.44-7.42 (d, J=8.4 Hz, 2H), 7.37-7.35 (d, J=8.4 Hz, 2H), 6.91-6.89 (d, J=8.4 Hz, 1H), 6.63-6.61 (d, J=8 Hz, 1H), 5.89 (s, 1H), 5.85-5.84 (d, J=2.4 Hz, 3H), 5.13 (s, 1H), 4.30-4.27 (d, J=9.6 Hz, 1H), 3.97-3.94 (m, 3H), 3.72 (s, 3H), 2.80-2.74 (m, 1H), 2.22-2.13 (m, 1H), 1.92-1.85 (m, 1H), 1.28-1.26 (m, 3H), 1.15- 1.01 (m, 4H). ESI-MS (m / z): 619.15 (M+H)+. EXAMPLE 10 ZRC-MC-241-WO Preparation of 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)cyclobutane-1-carboxylic acid Prepared using (DMSO-d6): 8.02 (s, 1H), 7.54- 2H) 7.01-6.99 (m, 1H) 6.91-6.90 (m, 1H) 5.88 (s, 1H), 5.82 (s, 1H) 5.61 (s, 1H) 5.41 (s, 1H) 4.53-4.51 (m, 1H) 4.50-4.49 (m, 1H) 4.10-4.07 (d, J= 10.4 Hz, 2H) 3.95 (m, 2H) 3.61 (s, 3H) 3.021 (m, 1H) 2.28-2.27. (m, 2H) 1.08 (s, 4H). ESI-MS (m / z): 617.11 (M+H)+. EXAMPLE 11 Preparation of 3-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)sulfonyl)propanoic acid Prepared using NMR (CDCl3): 12.54 (bs, 1H), 8.03 (s, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.21-7.13 (m, 1H), 7.08-7.01 (m, 1H), 6.99-6.88 (m, 2H), 6.58 (s, 2H), 5.59 (d, J = 7.6 Hz, 1H), 4.54 (d, J = 10.4 Hz, 1H), 4.05 (d, J = 10.8 Hz, 1H), 3.73 (s, 3H), 3.43-3.36 (m, 2H), 2.47-2.43 (m, 2H), 1.18-1.08 (m, 4H). ESI-MS (m / z): 639.15 (M+H)+. ZRC-MC-241-WO EXAMPLE 12 Preparation of 3-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)sulfonyl)propanoic acid (s, (d, , : (s, ZRC-MC-241-WO 1H ), 4.10-4.07 (d, J=10.4 Hz, 1H ), 3.67 (s, 3H), 1.14-1.05 (m, 4H). ESI-MS (m / z): 571.16 (M+H)+. EXAMPLE 14 Preparation of 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid : , 2- ZRC-MC-241-WO 6.61 (d, J=8.4 Hz, 1H), 6.00-5.99 (t, J=2 Hz, 1H), 5.97-5.96 (t, J=2 Hz, 1H), 5.91- 5.90 (t, J=2 Hz, 1H), 5.09 (s,1H), 4.30-4.28 (d, J=9.6 Hz, 1H), 3.99-3.97 (d, J=9.6 Hz, 1H), 3.74-3.71 (t, J=4.4 Hz, 3H), 3.54 (s, 2H), 2.32 (br, 1H), 1.23 (s, 6H), 1.14- 1.10 (m, 4H). ESI-MS (m / z): 591.22 (M+H)+. EXAMPLE 16 Preparation of 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- , 1- ZRC-MC-241-WO Prepared using intermediate IV-1 and intermediate V-15.1H NMR (DMSO-d6): 9.15 (s, 1H), 8.17 (s, 1H), 8.04 (s, 1H), 7.59-7.56 (d, J=12 Hz, 2H), 7.47-7.45 (d, J=8 Hz, 2H ), 7.02-7.01 (d, J=4 Hz, 1H ), 7.00-6.92 (m, 1H ), 6.84-6.83 (m, 1H), 6.67-6.66 (m, 1H), 6.35 (s, 1H), 5.66 (s, 1H), 4.58-4.55 (d, J=12 Hz, 1H), 4.11- 4.09 (d, J=8 Hz, 1H), 3.73 ( s, 3H), 1.16-1.13. (m, 4H). ESI-MS (m / z): 570.16 (M+H)+. EXAMPLE 18 Preparation of 2-(4-chlorophenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one Prepared using1 16. H NMR (DMSO-d6): 8.03 (s, 1H ), 7.57-7.55 (d, J=8Hz, 2H), 7.46-7.44 (d, J=8Hz, 2H), 6.99-6.99 (d, J=1.2Hz, 1H), 6.93-6.91 (d, J=8 Hz,1H ), 6.71-6.69 (d, J= 8 Hz, 1H), 6.49-6.47(d, J= 8 Hz, 1H ), 6.41 (s, 1H), 5.55 (s, 1H ), 4.56-4.54 (d, J=8 Hz, 1H), 4.08-4.06 (d, J= 8 Hz, 1H ), 3.68 (s ,3H), 1.56-1.52 (m, 6H), 1.17-1.05 (m, 4H). ESI-MS (m / z): 579.10 (M+H)+. EXAMPLE 19 Preparation of 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one ZRC-MC-241-WO Prepared using NMR (DMSO-d6): 8.03 (s, 1H), 7.54- , Hz, 2H), 7.01-6.98 (d, J=12 Hz, 1H), 6.93-6.91 (d, J=8 Hz, 1H), 6.51-6.49 (d, J=8.4 Hz, 1H), 5.919- 5.914 (d, J=2 Hz, 2H), 5.76-5.75 (t, J=2 Hz, 1H), 5.49-5.47 (d, J=8.4 Hz, 1H), 4.80- 4.77 (t, J=5.6 Hz, 1H), 4.53-4.51 (d, J=10.4 Hz, 1H), 4.15-4.12 (d, J=10.4 Hz, 1H), 3.86-3.79 (m, 2H), 3.66-3.61 (m, 4H), 1.21-1.09 (m, 4H). ESI-MS (m / z): 563.17 (M+H)+. EXAMPLE 20 Preparation of 2-(4-chlorophenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one Prepared using NMR (CDCl3): 8.18 (s, 1H), 7.45-7.42 (m, 2H), 7.38-7.36 (m, 2H), 6.92-6.89 (m, 1H), 6.62 (d, J=8.4 Hz, 1H), 5.95-5.89 (m, 3H), 5.16 (s, 1H), 4.28 (d, J = 9.6 Hz, 1H), 3.93 (d, =8.0 Hz, 1H), 3.72 (d, J = 4.0 Hz, 5H), 1.34 (s, 6H), 1.14-1.08 (m, 4H). ESI-MS (m / z): 591.19 (M+H)+EXAMPLE 21 ZRC-MC-241-WO Preparation of 2-(4-chlorophenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one (s, (d, -5- (s, (d, = ZRC-MC-241-WO EXAMPLE 23 Preparation of 2-(4-chlorophenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one : , , J= -5- : , , ZRC-MC-241-WO 4.53-4.50 ( d, J=10.4 Hz, 2H ) 4.13-4.106 (d, J=10.8Hz, 1H), 3.63 (s, 3H), 3.56- 3.51 (m, 2H) 1.52-1.08 (m, 4H). ESI-MS (m / z): 571.20 (M+H)+. EXAMPLE 25 Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile (s, (1- , (d, ZRC-MC-241-WO J=10.4 Hz, 1H), 3.72-3.71 (m, 2H), 3.61 (s, 3H), 1.24 (s, 2H), 1.08 (m, 4H), 0.45- 0.42. (m, 4H). ESI-MS (m / z): 603.12 (M+H)+. EXAMPLE 27 Preparation of 3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl methanesulfonate : J= (s, ZRC-MC-241-WO (m, 2H), 6.93-6.98 (m, 2H), 6.79 (s, 1H) 6.67(s, 1H), 6.29 (s, 1H) 5.66-5.64 (d, J=8 Hz, 1H), 4.44-4.41 (d, J=12 Hz, 1H), 4.11-4.08 (d, J=12 Hz, 1H) 3.91 (s, 3H), 3.72 (s, 3H) 1.19-1.17 (m, 1H), 1.11-1.08 (m, 3H). ESI-MS (m / z): 600.20 (M+H)+. EXAMPLE 29 Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one Prepared using (DMSO-d6): 8.01 (s, 1H ), 7.34-7.32 ( d, J=8 Hz, 1H), 7.14 (s, 1H), 7.04-6.98 (m, 2H), 6.92-6.90 (d, J=8 Hz, 1H), 6.74-6.65 (m, 2H), 6.49-6.46 (d, J=12 Hz, 1H), 6.33 (s, 1H), 5.62-5.60 (d, J=8 Hz, 1H), 4.42-4.39 (d, J= 12 Hz, 1H ), 4.07-4.05(d, J=8 Hz, 1H), , 3.88 (s, 3H), 3.67 (s, 3H), 1.64-1.61 (m, 6H), 1.19-1.07 (m, 4H). ESI-MS (m / z): 609.20 (M+H)+. EXAMPLE 30 Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one ZRC-MC-241-WO Prepared using intermediate VI-1, II-1 and V-7.1H NMR (DMSO-d6): 8.01 (s, 1H), 7.32-7.30 (d, J=8.4 Hz, 1H), 7.13 (s, 1H), 7.04-6.98 (m, 2H), 6.93-6.91 (d, J=8.4 Hz, 1H), 6.51-6.48 (d, J=8.8 Hz, 1H), 5.84 (s, 2H), 5.75 (s, 1H), 5.54-5.52 (d, J=8.8 Hz, 1H), 4.51-4.49 (t, J=5.2 Hz, 1H), 4.39-4.37 (d, J=10.4 Hz, 1H), 4.14-4.12 (d, J=10.4 Hz, 1H), 3.91-3.85 (m, 5H), 3.60 (s, 3H), 3.52-3.48 (m, 2H), 1.81-1.75 (m, 2H), 1.18-1.11 (m, 4H). ESI-MS (m / z): 607.15 (M+H)+. -5- (d, (t, (d, 3- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one ZRC-MC-241-WO Prepared using (CDCl3): 8.18 (s, 1H), 7.38 (d, J = 8.4 Hz, , = , (d, J = 1.6 Hz, 1H), 6.89-6.87 (m, 1H), 6.61 (d, J = 8.0 Hz, 1H), 5.88 (s, 3H), 5.58 (s, 1H), 4.23 (d, J = 10 Hz, 1H), 4.11 (t, J = 6.2 Hz, 2H), 3.97-3.95 (m, 4H), 3.73 (s, 3H), 1.96 (t, J = 6.2 Hz, 2H), 1.31 (s, 6H), 1.15-1.10 (m, 4H). ESI-MS (m / z): 635.19 (M+H)+. EXAMPLE 33 Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)- 5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one Prepared using (DMSO-d6): 8.01 (s, 1H), 7.30-7.28 (d, J= 8.4 Hz, 1H), 7.14-7.14 (d, J=8.8 Hz, 1H), 7.04-6.99 (m, 2H ), 6.93-6.91 (d, J=8.4 Hz, 1H ), 6.65-6.63 (d, J=8.8 Hz, 1H ), 6.28 (s, 1H), 6.22 ( s, 1H), 6.17 (s, 1H), 5.56-5.53 (d, J= 8.8 Hz, 1H), 4.87-4.84 (t, J=5.2 Hz, 1H), 4.39- 4.36 (d, J=10.4 Hz, 2H ), 4.15-4.13 (d, J=10.4 Hz, 1H), 3.89 (s, 3H), 3.63 (s, 3H), 3.56-3.51 (m, 2H), 1.24 (s, 2H), 1.16-1.08 (m, 4H). ESI-MS (m / z): 601.40(M+H)+. EXAMPLE 34 ZRC-MC-241-WO Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxyprop-1-yn-1- yl)-5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethan-1-one Prepared using (DMSO-d6): 8.02 (s, 1H), 7.30-7.28 (d, , , 7.04-6.99 (m, 2H), 6.93-6.91 (d, J=8.4 Hz, 1H ), 6.71-6.69 (d, J=8.8 Hz, 1H), 6.31- 6.20 (m, 3H), 5.56- 5.545 (d, J=8.4 Hz, 1H), 5.29-5.24 (m, 1H), 4.39-4.38 (d, J=5.6 Hz, 1H), 4.25-4.23 (d, J=6.0 Hz, 2H ), 4.15-4.13 (d, J=10.4 Hz, 1H ), 3.89 (s, 3H), 3.64 (s, 3H), 1.19- 1.08 (m, 4H).ESI-MS (m / z): 587.17 (M+H)+. EXAMPLE 35 Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2- methylpropoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one Prepared using intermediate VI-1, II-1 and V-13.1H NMR ( DMSO-d6): 8.02 (s, 1H), 7.33-7.31 (d, J=8.4 Hz, 1H), 7.14-7.13 (d, J=2 Hz, 1H), 7.04-6.98 (m, 2H), 6.93-6.91 (d, J=8.4 Hz, 1H), 6.52-6.49 (d, J=8.4 Hz, 1H), 5.87-5.83 (d, J=14 Hz, 2H) 5.76 (s, 1H), 5.55-5.53 (d, J=8.8 Hz, 1H), 4.56 (s, 1H), 4.40-4.37 (d, J=10.4 ZRC-MC-241-WO Hz, 1H), 4.14-4.12 (d, J=10.4 Hz, 1H), 3.89 (s, 3H), 3.61 (s, 3H), 3.58-3.51 (m, 2H), 1.19-1.08 (m, 10H). ESI-MS (m / z): 621.17 (M+H)+. EXAMPLE 36 Preparation of 2-(1-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile , . , ZRC-MC-241-WO 1H), 6.92-6.90 (d, J=8.4, 1H), 6.48-6.46 (d, J=8.1, 1H),5.84 (s, 1H), 5.72 (s, 1H), 5.67-5.66 (t, J=2.01H), 5.48-5.46 (d, J=8.8, 1H), 4.39-4.37 (d, J=10.41H), ), 4.13- 4.11 (d, J=10.41H) 3.87 (s, 3H), 3.57(s, 3H), 1.39 (s, 6H), 1.19-1.06 (m, 4H). ESI- MS (m / z): 635.14 (M+H)+EXAMPLE 38 Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclobutane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid Prepared using1HNMR (DMSO-d6): .12.19 (s, 1H), 8.33-8.03 (m, 1H), 7.60-7.58 (d, J=8.4 Hz, 2H), 7.53-7.51 (d, J=8.4 Hz, 2H), 7.455-7.43 (m, 1H), 7.25-7.21 (m, 1H), 7.19-7.17 (m, 1H), 7.11-7.10 (s, 1H), 6.43-6.35 (m, 1H), 5.98-5.97 (d, J=8 Hz, 1H), 5.76-5.57 (m, 1H), 5.60 (s, 1H), 4.65-4.62 (d, J=11.2 Hz, 1H), 3.86-3.84 (m, 2H), 3.76-3.62 (m, 2H), 3.56 (s, 3H), 2.34-3.32 (m, 5H), 2.17-2.03 (m, 2H), 1.98-1.84 (m, 2H). ESI-MS (m / z): 533.15 (M-H). EXAMPLE 39 Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopentane-1,3'- indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid ZRC-MC-241-WO Prepared using intermediate IV-3 and intermediate V-4.1HNMR (DMSO-d6): 8.05- 8.03 (d, J=8 Hz,1H), 7.60-7.58 (d, J=8.4 Hz, 2H), 7.45-7.43 (d, J=8.4 Hz, 2H), 7.26-7.24 (m, 1H), 7.17-7.15 (m, 1H), 7.08-7.06 (m, 1H), 6.36-6.34 (s, J=8.8 Hz, 1H), 5.98-5.97 (d, J=8 Hz, 1H), 5.76-5.57 (m, 1H), 5.50-5.47 (m, 1H), 4.28-4.26 (d, J=10.4 Hz, 1H), 3.86-3.84 (m, 2H), 3.76-3.62 (m, 2H), 3.62 (s, 3H), 2.33-3.31 (m, 2H), 1.90-1.72 (m, 9H). ESI-MS (m / z): 547.19 (M-H). (t, (d, , methoxyphenoxy)acetic acid ZRC-MC-241-WO Prepared using : 606.21 (M+H)+EXAMPLE 42 Preparation of 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid Prepared using DMSO-d6): 12.41 (s, 1H), 8.01 (s, 1H), 7.32-7.30 (d, J=8.4 Hz, 1H), 7.13-7.12 (d, J=2 Hz, 1H), 7.04- 6.99 (m, 2H), 6.93-6.91 (d, J=8.4 Hz, 1H), 6.54-6.52 (d, J=8.8 Hz, 1H), 5.84 (s, 2H), 5.75 (s, 1H), 5.54-5.52 (d, J=8.4 Hz, 1H), 4.39-4.36 (d, J=10.4 Hz, 1H), 4.15- 4.13 (d, J=10 Hz, 1H), 4.05-3.97 (m, 2H), 3.88 (s, 3H), 3.60 (s, 3H), 2.63-2.60 (t, J=6 Hz, 2H), 1.26-1.08 (m, 4H). ESI-MS (m / z): 621.14 (M+H)+. EXAMPLE 43 Preparation of 3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl methanesulfonate ZRC-MC-241-WO +. 2- (s, ), ZRC-MC-241-WO Prepared using : 633.18 (M+H)+. Preparation of 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy) propanenitrile Prepared using d6): 8.02 (s,1H), 7.32-7.30 (d, J=8 Hz,1H ), 7.139-7.134 (d, J=22.4 Hz,1H ), 7.04-6.98 (m,2H ), 6.93-6.91(d, J=8 Hz, 1H), 6.57-6.55 ( d, J=8 Hz, 1H ), 5.89-5.87 (d, J=8 Hz, 2H), 5.79 (s, 1H), 5.56-5.54 (d, J=8 Hz, 1H), 4.40-4.37 (d, J=12 Hz, 1H), 4.14-4.12 (d, J=8 Hz, 1H), 4.05-4.01(m, 2H), 3.89 (s, 3H), 3.62 (s, 3H), 2.95-2.92 (t, J=8 Hz, 2H), 1.18-1.08 (m, 4H). ESI-MS (m / z): 602.16 (M+H)+. EXAMPLE 47 Preparation of 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid ZRC-MC-241-WO Prepared using DMSO-d6): 12.31 (s, 1H), 8.01 (s, 1H), 7.32-7.30 (d, J=8 Hz, 1H), 7.13-7.12 (d, J=1.6 Hz, 1H), 7.04- 6.98 (m, 2H), 6.93-6.91 (d, J=8 Hz, 1H), 6.51-6.49 (d, J=8.4 Hz, 1H), 5.85-5.84 (d, J=5.6 Hz, 2H), 5.76 (s, 1H), 5.54-5.52 (d, J=8.4 Hz, 1H), 4.39-4.37 (d, J=10.4 Hz, 1H), 4.14-4.11 (d, J=10.4 Hz, 1H), 3.88 (s, 3H), 3.84-3.78 (m, 2H), 3.60 (s, 3H), 2.35-2.31 (t, J=7.2 Hz, 2H), 1.88-1.83 (m, 2H), 1.19-1.08 (m, 4H). ESI-MS (m / z): 635.16 EXAMPLE 48 Preparation of 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile Prepared using (DMSO-d6): 8.01 (s, 1H), 7.54-7.52 (d, J=8.4 Hz, 2H, 7.45-7.43 (d, J=8.4 Hz, 2H, 6.99-6.98 (m, 1H) 6.91-6.90 (m, 1H), 6.51-6.46 (d, J=8.4 Hz, 2H) 5.94-5,93 (m, 1H) 5.78-5.77 (m, 1H) 5.50-5.48 ( d, J=8.4 Hz, 1H) 4.54-4.51 ( d, J=8.4 Hz, 1H) 4.11-4.09 (d, J=8.4 ZRC-MC-241-WO Hz, 1H) 3.73 (s, 2H), 3.61 (s, 3H) 2.70 (s, 2H) 1.14-1.13 (m, 1H), 1.10-1.108 (m, 3H), 0.62 (s, 4H). ESI-MS (m / z): 612.14 (M+H)+. EXAMPLE 49 Preparation of 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid To a stirring 13 (0.07 g, 0.123 mmol) in 50% Methanol: THF (3 mL) was added Pd-C (0.013 g, 0.123 mmol) and the reaction mixture was stirred at room temperature for 2 hrs. After the complete conversion of starting material, the reaction mixture was filtered through celite and washed with methanol, evaporated under reduced pressure, and purified by column chromatography to get the title product.1H NMR (DMSO-d6): 12.1 (s, 1H), 8.03 (s, 1H), 7.55-7.53 (d, J=8.4 Hz, 2H), 7.44-7.42 (d, J=8.4 Hz, 2H), 7.00-6.98 (m, 1H), 6.93-6.91 (m, 1H), 6.43-6.41 (d, J=8.4 Hz, 1H ), 6.22 (s, 1H), 6.11 (s, 1H ), 6.04 (s, 1H), 5.49-5.47 (d, J=8.8 Hz, 1H ), 4.54-4.52 (d, J=10.8 Hz, 1H ), 4.10-4.07 (d, J=10.8 Hz, 1H), 3.34 (s, 3H) 2.65-2.611 (m, 2H), 2.46-2.300 (m, 2H), 1.23-1.04 (m, 4H). ESI-MS (m / z): 575.11(M+H)+. EXAMPLE 50 Preparation of 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid ZRC-MC-241-WO Prepared using process similar as described for EXAMPLE 51 Preparation of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-N-(methylsulfonyl)butanamide To a stirring 1 (400 mg, 0.618 mmol) in DCM (15 mL) was added EDC.HCl (239 mg, 1.26 mmol) followed by DMAP (7.9 mg, 0.069 mmol) and the resulting mixture was stirred at room temperature for 1 hr. To this methane sulfonamide was added (118 mg, 1.24 mmol) and the resulting mixture was stirred at room temperature for 12 hrs. After complete conversion of the starting material, the reaction mixture was diluted with cold water, acidify with aqueous HCl and extracted with DCM. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product.1H NMR (CDCl3): 11.71 (s, 1H), 8.03 (s, 1H), 7.51 (d, J=8.4 Hz, 2H), 7.43 (d, J=8.4 ZRC-MC-241-WO Hz, 2H), 6.98 (d, J=1.6 Hz, 1H), 6.91 (d, J=8.4 Hz, 1H), 6.50 (s, 1H), 5.92-5.91 (m, 2H), 5.76-5.75 (m, 1H), 5.41 (s, 1H), 4.50 (d, J=10.4 Hz, 1H), 4.09 (d, J=10.4 Hz, 1H), 3.83 (t, J=6.2 Hz, 2H), 3.61 (s, 3H), 3.23 (s, 3H), 2.42-2.33 (m, 2H), 1.89 (t, J=6.6 Hz, 2H), 1.14-1.13 (m, 4H). ESI-MS (m / z): 682.4 (M+H)+. EXAMPLE 52 Preparation of (3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine Step 1: -2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycinate To a stirring solution of the product example 14 (250 mg, 0.423 mmol) and methyl glycinate hydrochloride (63.7 mg) in DCM (20 mL) was added HOBt (12.96 mg, 0.085mmol) and DIPEA (0.148 ml, 0.846 mmol) followed by EDC.HCl (122 mg, 0.635 mmol). The resulting mixture was stirred at room temperature for 5 hr. After complete conversion of the starting material, the reaction mixture was diluted with cold water and the organic layer was separated, washed with water and evaporated under reduced pressure to get the title product. ESI-MS (m / z): 662.13 (M+H)+. ZRC-MC-241-WO Step 2: Preparation of (3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine To a stirring 0.068 mmol) in THF (2 ml) was a mg, 0.204 mmol) in water (2 ml). The resulting mixture was stirred at RT for 2 hrs. After complete conversion of starting material, the reaction mixture was acidified with dil. HCl and the product was extracted in ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get the title product.1H NMR (DMSO-d6): 8.02 (s, 1H), 7.83 (s, 1H), 7.54-7.52 (d, J=8.4 Hz, 2H), 7.44-7.42 (d, J=8.4 Hz, 2H), 7.00-6.98 (d, J=9.6 Hz, 1H), 6.93-6.91 (d, J=8 Hz, 1H), 6.51-6.49 (d, J=8.8 Hz, 1H), 5.93-5.91 (d, J=9.6 Hz, 2H), 5.75 (s, 1H), 5.51-5.49 (d, J=8.8 Hz, 1H), 4.55-4.52 (d, J=10.4 Hz, 1H), 4.13-4.10 (d, J=10.4 Hz, 1H), 4.04-4.01 (t, J=6 Hz, 2H), 3.61 (s, 3H), 3.58-3.55 (m, 2H), 2.55-2.50 (m, 2H), 1.18-1.08 (m, 4H). ESI-MS (m / z): 648.16 (M+H)+EXAMPLE 53 Preparation of (3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine ZRC-MC-241-WO Prepared similar process described for example 52. ESI-MS (m / z): 678.19 (M+H)+. EXAMPLE 54 Preparation of 2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5-(1H- 1,2,4-triazol-1-yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethan-1-one Step 1: Preparation oxy)ethoxy)-4- chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)acetate To a stirring solution of VI-2 (1.3 g, 2.88 mmol) in DMF (15 mL) was added intermediate V-15 (0.83 mg, 2.59 mmol) followed by triethyl amine (1.28 mL, 8.64 mmol) and the resulting mixture was heated at 80°C for 12 hrs. After the complete conversion of starting material, the reaction mixture ZRC-MC-241-WO was diluted with cold water, extracted with ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. Step 2: Preparation of 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4- chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)acetic acid To a stirring solution of step 1 (600 mg, 1.15 mmol) in 50% methanol: THF (10 was aqueous solution of sodium hydroxide (131 mg, 3.39 mmol) and the resulting mixture was stirred at room temperature for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water, acidify with citric acid and extracted with DCM, it was evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. ESI-MS (m / z): 533.18 (M+H)+Step 3: Preparation of 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4- chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one To a stirring solution of step 2 (1.5 g, 2.25 mmol) in DMF (20 ml) was added product obtained from intermediate II-1 (0.517 g, 2.25 mmol) followed by HATU (1.28 g, 3.38 mmol) and DIPEA (1.18 mL, 6.76 mmol) at 0-10°C and the resulting mixture was stirred at room temperature for 1 hr. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, ZRC-MC-241-WO evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 744.22 (M+H)+Step 4: Preparation of 2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5- (1H-1,2,4-triazol-1-yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethan-1-one 3 (0.8 g, 0.913 mmol) in DCM (10 mL) was added TFA (0.70 mL, 9.13 mmol) at 0°C and the resulting mixture was stirred at room temperature for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water and extracted with DCM. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product.1H NMR (DMSO-d6): 9.12 (s, 1H), 8.16 (s,1H), 8.04 (s, 1H), 7.41-7.39 (d, J=8 Hz, 1H), 7.15-.714 (d, J=4 Hz, 1H), 7.09- 6.98 (m, 2H), 6.97-6.84 (m, 3H), 6.66-6.65 (m, 1H), 6.36 (s, 1H), 5.79-5.77 (d, J=8 Hz, 1H), 5.01 (s, 1H), 4.48-4.45 (d, J=12 Hz, 1H), 4.20-4.06 (m,3H), 3.84 (s, 1H), 3.76-3.72 ( m, 4H), 1.18-1.02 (m, 4H). ESI-MS (m / z): 630.14 (M+H)+. EXAMPLE 55 Preparation of (+) 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile ZRC-MC-241-WO : (d, ZRC-MC-241-WO 1H), 4.11-4.09 (d, J=10.4 Hz, 1H), 3.74 (s, 2H), 3.61 (s, 3H), 2.70 (s, 2H), 1.14- 1.13 (m, 1H), 1.10-1.108 (m, 3H), 0.62 (s, 4H). ESI-MS (m / z): 612.18 (M+H)+. Example NAME ESI- No. MS(m / z): ZRC-MC-241-WO yl)ethyl)amino)-5-methoxyphenoxy)-N- (methylsulfonyl)butanamide ZRC-MC-241-WO 73 (+)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- 591.12 (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- ZRC-MC-241-WO yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine ZRC-MC-241-WO 90 (-)-2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3- 630.13 methoxy-5-(1H-1,2,4-triazol-1-yl)phenyl)amino)-1- ZRC-MC-241-WO (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- yl)ethan-1-one ZRC-MC-241-WO 106 (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2- 621.18 methylpropoxy)-5-methoxyphenyl)amino)-1-(6'- ZRC-MC-241-WO methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- ZRC-MC-241-WO 121 (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- 586.15 (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'- ZRC-MC-241-WO (6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one Assy protocol to screen compounds using RT-PCR VeroE6 cells, mycoplasma free are seeded at the density of 25,000 cells / well in 100 µl / well in 96 well plate in complete MEM (Plain MEM + 10% FBS+ 1X antibiotics) and incubated overnight at 37 °C, 5% CO2. Next day, the required virus (DENV2 NGC Strain -New Guinea C) of 106PFU / mL in plain MEM at 0.05 MOI is added to the cells and incubated for 1 h at 37°C, 5% CO2. After 1 h, virus was removed and compounds were added at required concentrations. After 48 h, RNA was isolated from the supernatant. It is then reverse transcribed to cDNA and amount of virus detected by RT-PCR. Following the denaturation at 95 °C for 5 minutes, the RT-PCR was run for 45 cycles for 95 °C for 10 second, 60 °C 30 second. Delta delta CT was calculated for all CT values. % inhibition was calculated by considering DMSO delta delta CT as 100-% inhibition. Inhibitory concentration (50%) was derived from plotting the data in Graph pad prism and performing non- linear regression analysis. Biological Data: Example No DENV2 IC50(nM) 1 ZRC-MC-241-WO 10 0.8 11 2 Examples 16, 40, 41, 42, 43, 44, 45, 46, 47, 50, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130 have shown DENV2 IC50 value in the range of less than 200 nM. ZRC-MC-241-WO The novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known. The novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs are useful as a medicament for the mammalian infections and suitable for humans and other warm-blooded animals, and may be administered either by oral, topical or parenteral administration. The quantity of the active component, that is, the novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs and unit dosage form thereof may be varied or adjusted widely depending upon several factors such as the particular application method, the potency of the particular compound and the desired concentration. Use of the novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs for the treatment of virus-related disorders such as Dengue. A method of treatment of virus-related disorders such as Dengue by administering to a subject in need thereof a therapeutically effective amount of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs.

Claims

ZRC-MC-241-WO We claim:

1. A novel compound of the general formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs,X is selected from aryl, heteroaryl or heterocyclyl ring; R1is selected from hydrogen, halogen, haloalkyl, (C1-C6)alkyl, heterocyclyl, -OR4; where (C1-C6)alkyl, heterocyclyl are independently unsubstituted or substituted with one or more suitable substituents; Y is selected from carbocyclic ring or heterocyclic ring, which are independently unsubstituted or substituted with one or more suitable substituents selected from (C1-C6)alkyl, -OR4, halogen; A and B are selected from carbocyclic or heterocyclic ring; R2 and R3 are selected from hydrogen, hydroxy, cyano, halo, nitro, - -ZRC-MC-241-WO R4 and R5 are independently selected from hydrogen, unsubstituted or substituted (C1-C6)alkyl, (C3-C6)cycloalkyl, haloalkyl; R4and R5together with the N atom to which they are attached may form a 5-8 membered heterocyclyl or heteroaryl ring; In an embodiment, when any of the (C1-C6)alkyl, (C2-C6)alkenyl, (C2- C6)alkynyl, (C3-C6)cycloalkyl are substituted; the suitable substitutions on them may be selected from hydrogen, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy, -COR4, -COOR4, -OR4, -S(O)pR4, - NR4R5, -CONR4R5, -CON(R4)OR5, -CON(R4)SO2R5, -N(R4)COR5, - N(R4)COOR5, -N(R4)CONR4R5, -SO2NR4R5, -N(R4)SO2R5 derivatives; R4 and R5are same as described above; p is selected from integers from 0-2; l is selected from integers from 1-4; m is selected from integers from 1-5; n is selected from integers from 1-5.

2. The compound of formula (I) as claimed in claim 1, wherein X is aryl; R1 is hydrogen, -OR4; Y is selected from carbocyclic ring and heterocyclic ring; A and B is selected from carbocyclic; R2and R3afe selected from halo, (C2- ;(C1- C6)alkyl, (C3-C6)cycloalkyl.

3. Compounds of the formula (I) as claimed in claim 1: 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile;ZRC-MC-241-WO 2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopropane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; (5S)-5-(2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-one; (2S)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-hydroxybutanoic acid; (2S)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methoxybutanoic acid; 2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylbutanoic acid; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)cyclobutane-1-carboxylic acid; 3-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)sulfonyl)propanoic acid; 3-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)sulfonyl)propanoic acid;ZRC-MC-241-WO 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propiolic acid; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; 2-(4-chlorophenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanenitrile; 2-(4-chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(dimethylphosphoryl)-5-methoxyphenyl)amino)- 1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1- one; 2-(4-chlorophenyl)-2-((3-(2-hydroxyethoxy)-5-methoxyphenyl)amino)-1- (6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(3-hydroxypropoxy)-5-methoxyphenyl)amino)- 1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1- one; 2-(4-chlorophenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one;ZRC-MC-241-WO 2-(4-chlorophenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile; 2-(4-chlorophenyl)-2-((3-((1-(hydroxymethyl)cyclopropyl)methoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; 2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one;ZRC-MC-241-WO 2-(4-chloro-2-methoxyphenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; 2-(1-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; 2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclobutane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopentane-1,3'-indolin]-1'- yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(2',3',5',6'-tetrahydrospiro [indoline- 3,4'-pyran]-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; 2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; 3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate;ZRC-MC-241-WO 2-(4-chloro-2-methoxyphenyl)-2-((3-((1-hydroxy-2-methylpropan-2- yl)oxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-((1-(hydroxymethyl) cyclopropyl)methoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy) propanenitrile; 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; 3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; 3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-N-(methylsulfonyl)butanamide; (3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine; (3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine;ZRC-MC-241-WO 2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5-(1H-1,2,4- triazol-1-yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethan-1-one; (+) 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; (-) 2-(1-((3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(spiro[cyclopropane-1,3'-indolin]- 1'-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; (+)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; (-)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanoic acid; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-N-(methylsulfonyl)butanamide; (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-N-(methylsulfonyl)butanamide;ZRC-MC-241-WO (+)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; (-)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; (+)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; (-)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)acetic acid; (+)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; (-)-2-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid ; (+)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; (-)-2-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)-2-methylpropanoic acid; (+)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; (-)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid;ZRC-MC-241-WO (+)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; (-)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoic acid; (+)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; (-)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; (+)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; (-)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenyl)propanoic acid; (+)-(3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine; (-)-(3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine; (+)-(3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine; (-)-(3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanoyl)glycine;ZRC-MC-241-WO (+)-2-(4-chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(1H-1,2,4-triazol-1- yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5-(1H-1,2,4- triazol-1-yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-(2-hydroxyethoxy)phenyl)-2-((3-methoxy-5-(1H-1,2,4- triazol-1-yl)phenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane- 1,3'-indolin]-1'-yl)ethan-1-one; (+)-3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; (-)-3-((1-(4-chlorophenyl)-2-oxo-2-(6'-(trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; (+)-3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate; (-)-3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenyl methanesulfonate;ZRC-MC-241-WO (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(dimethylphosphoryl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxyethoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxypropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one;ZRC-MC-241-WO (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(2-hydroxy-2-methylpropoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-((1-hydroxy-2-methylpropan-2-yl)oxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-hydroxy-2-methylpropan-2- yl)oxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-hydroxy-2-methylpropan-2- yl)oxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxy-3-methylbutoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-((1-(hydroxymethyl)cyclopropyl)methoxy)- 5-methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-((1-(hydroxymethyl)cyclopropyl)methoxy)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one;ZRC-MC-241-WO (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-(hydroxymethyl) cyclopropyl)methoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-((1-(hydroxymethyl) cyclopropyl)methoxy)-5-methoxyphenyl)amino)-1-(6'- (trifluoromethoxy)spiro [cyclopropane-1,3'-indolin]-1'-yl)ethan-1-one; (+)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanenitrile; (-)-3-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)propanenitrile; (+)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy) propanenitrile; (-)-3-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'-(trifluoromethoxy) spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5-methoxyphenoxy) propanenitrile; (+)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile; (-)-4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile; (+)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile; (-)-4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)butanenitrile;ZRC-MC-241-WO (+)-2-(1-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; (-)-2-(1-((3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6'- (trifluoromethoxy)spiro[cyclopropane-1,3'-indolin]-1'-yl)ethyl)amino)-5- methoxyphenoxy)methyl)cyclopropyl)acetonitrile; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(3-hydroxyprop-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(4-hydroxybut-1-yn-1-yl)-5- methoxyphenyl)amino)-1-(6'-(trifluoromethoxy)spiro[cyclopropane-1,3'- indolin]-1'-yl)ethan-1-one.

4. Use of the novel compound of general formula (I) as claimed in claim 1 for the treatment of virus-related disorder selected from dengue.

5. Use of the compound of general formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs as claimed in claim 1 in the manufacture of a medicament for the treatment of virus-related disorder selected from dengue.

6. Pharmaceutical compositions comprising compounds of general formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs as claimed in claim 1 and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, binder, disintegrant, coating agent, filler, glidant, and / or other suitable excipients.

Images